MolVerity AI is built as a platform, not a single model. ToxVerity is the first product today; ADMET Intelligence and the MolVerity API extend the same reliability-centered architecture as they become available.
AI-powered toxicity intelligence for early small-molecule screening.
Future capabilities spanning absorption, distribution, metabolism and excretion.
Future programmatic access for cheminformatics and compound-management pipelines.
Private cloud and on-premise deployment for stricter data requirements.
ToxVerity evaluates molecular candidates across six research toxicity endpoints while assessing calibration, uncertainty, applicability domain, scaffold novelty and out-of-distribution status.
Planned web access for research organizations at app.molverity.com.
For organizations requiring greater confidentiality and control over molecular data and infrastructure.
Future deployment for organizations requiring candidate structures to remain within their infrastructure.
Proprietary molecular structures are commercially sensitive intellectual property. These principles guide the commercial architecture as capabilities are built and validated.
Data in transit is encrypted in commercial deployment.
Data at rest is protected in commercial deployment.
Customer data separation is a core architecture objective.
Access is planned to be scoped by role.
Retention controls are planned for commercial deployment.
Activity traceability is part of the enterprise roadmap.
Predictions are designed to be traceable to model versions.
Customer-controlled deletion is part of the deployment roadmap.
The planned API is intended for high-throughput screening, cheminformatics integration, programmatic result retrieval and reproducible model-version tracking.
POST /v1/screen
{
"library": "smiles[]",
"endpoints": "all",
"model_version": "pinned"
}Book a walkthrough of ToxVerity or discuss a pilot on your own molecular library.